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Within the past five years, two classes of per- and polyfluoroalkyl substances (PFAS) were 
phased out of production in the U.S., which led to the development and production of PFAS to 
replace these two major classes. One family of these PFAS are perfluoro-ether carboxylic acids 
(PFECA), which have emerged in the public and scientific arenas due to their presence in 
drinking water systems across the U.S., including Wilmington, NC. Although manufacturers 
have touted them as having more favorable environmental and toxicological properties very 
little is known about the toxicity and environmental fate these emerging PFECA. One 
compound, perfluoro-2-methoxyacetic acid (PFMOAA), was identified as the dominant PFECA 
in the Cape Fear River, in concentrations as high as 35,000 ng/L. There is very little mention of 
PFMOAA in the publicly available scientific literature and to our knowledge, we are the first to 
investigate its potential for toxic effects. In this 30-day study, we orally administered 25,000, 
2,500,000, or 250,000,000 ng/L of PFMOAA in water to male and female C57BL/6 mice and 
investigated immune and liver alterations following exposure. Mice given PFMOAA showed no 
signs of overt toxicity during the study and no evident changes were observed in liver mass or 
peroxisomal enzyme activity. While mild alterations in splenic and thymic lymphocyte sub-
populations were observed in males, these results do not point to any definitive alterations in 
immune function. Ultimately, we concluded that the doses administered were too low to achieve 
an internal dose sufficient to induce changes to immune endpoints, likely due to rapid excretion 
of PFMOAA in mice. Further investigation into serum and organ concentrations of PFMOAA 
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CHAPTER 1: INTRODUCTION 
Legacy PFAS 
Per- and polyfluoroalkyl substances (PFAS) are a large family of amphiphilic compounds 
composed of alkane tails with fluorine replacing some or all the hydrogens and an active head 
group (Wang et al., 2017). This family of chemicals is estimated to contain over 5,000 different 
compounds that are widely utilized throughout the world in manufacturing and consumer 
products for their chemical properties that confer water, oil and stain resistance as well as 
temperature and friction resistance (ATSDR, 2018; US EPA, 2019). These chemical properties 
have made them abundant in water-resistant coatings for textiles and paper products, non-stick 
coatings on cookware and food packaging, and to formulate firefighting foams as well as use in 
aerospace, electronics and automotive industries (ATSDR, 2018; FluoroCouncil, 2014; NTP, 
2016). Conversely, these same properties of the strong carbon-fluorine bond and amphiphilic 
characteristics have raised environmental health concerns. The carbon-fluorine bonds do not 
readily break down in the environment and make these compounds highly mobile in soil and 
water as well as bioaccumulative (US EPA, 2018; Wang et al., 2017). The Centers for Disease 
Control and Prevention (CDC), through their National Health and Nutrition Examination Survey 
(NHANES), a cross-section representative of the U.S. general population, detected PFAS in the 
majority of participants (ATSDR, 2018). Olsen et al., (2017) also detected PFAS in serum from 
American blood donors collected from 2000-2015, further contributing to the evidence of PFAS 
as major environmental contaminants that also get into humans. 
While the PFAS family of compounds is extensive, two PFAS chemicals, 
perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in particular, have been 
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heavily studied and identified by the U.S. Environmental Protection Agency (US EPA) as 
developmental toxicants (US EPA, 2016a, 2016b) and by the U.S. National Toxicology Program 
(US NTP) as presumed to immune hazards to humans (NTP, 2016). PFOA was first synthesized 
in the early 1940s by scientists working at DuPont; it was later primarily applied as a production 
aid for fluoropolymers used in non-stick coatings (Buck et al., 2011). One such fluoropolymer, 
TeflonTM, became widely used, and its production became one of the major sources of PFAS 
release into the environment (Sajid et al., 2017). In the 1950s, a scientist working at the 3M 
Company spilled an experimental fluorochemical on a shoe and later noticed that the shoe 
repelled water and dirt (3M, 1999; ATSDR, 2018). This led to the invention of PFOS, which was 
trademarked as ScotchgardTM (ATSDR, 2018). The manufacture and use of these and other 
PFAS in water-repellent outerwear, food packaging, and aqueous film forming foams (AFFF), as 
well as many other products have led to the widespread release of PFAS into the environment. 
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Table 1. List of several PFAS compounds including, structure, name, abbreviation, chemical formula, and CAS number. 






PFOA Perfluorooctanoic acid C8HF15O2 335-67-1 
 




PFDA Perfluorodecanoic acid C10HF19O2 335-76-2 
 
PFHxA Perfluorohexanoic acid C6HF11O2 307-24-4 
 












PFMOAA Perfluoro-2-methoxyacetic acid C3HF5O3 674-13-5 




Absorption, Distribution Metabolism and Excretion 
Humans can absorb PFAS through contaminated drinking water and food as well as by 
dust inhalation and hand to mouth contact from coated surfaces such as carpets and clothing 
(Fraser et al., 2013; Hopkins et al., 2018; US EPA, 2018; Wu et al., 2019). PFAS also are known 
to cross the placental barrier, have been measured in fetal cord blood as well as breast milk, 
leading to an increased exposure risk to infants (ATSDR, 2018; Impinen et al., 2019; Manzano-
Salgado et al., 2015). Once absorbed into the body, they can enter circulation where PFAS 
primarily bind to albumin and other serum proteins (ATSDR, 2018). Binding to serum proteins 
leads to accumulation of PFAS in organs including the kidneys, spleen, and thymus, and in the 
highest extravascular concentrations in the liver (ATSDR, 2018; Gomis et al., 2018). There is no 
evidence that PFAS undergo metabolism in the body and are primarily excreted in the urine 
(ATSDR, 2018; US EPA, 2018). In females, PFAS can also be eliminated through menstrual 
blood, which according to Wong et al. (2014), has been shown to contribute to many of the sex 
differences observed in PFAS elimination in humans. It also is hypothesized that male and 
female rodents, especially rats, have differences in renal tubular reabsorption channels, but this 
still requires further investigation to determine if this also is true for humans (ATSDR, 2018; 
Chang et al., 2008). The long alkane chains of PFAS act similarly in the body to fatty acids, and 
these properties, including their distribution and excretion rates, are heavily dependent on chain 
length. In general, half-lives of PFAS are correlated with chain length and branching; longer 
chain PFAS are excreted more slowly, sulfonates are excreted more slowly than carboxylates, 
and branched chains are excreted more rapidly (ATSDR, 2018; Peng et al., 2013; Zhang et al., 
2013). PFOA for example has a half-life in humans of approximately 3.4 years, PFOS is slightly 
longer at 4.3 years, perfluorodecanoic acid (PFDeA) has an approximate half-life of 8.3 years, 
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and perfluorobutanoic acid (PFBA) has a half-life of approximately 72 hours (ATSDR, 2018). 
There are exceptions to the general rule as the six carbon perfluorohexane sulfonic acid (PFHxS) 
has an average half-life of 8 years, longer than its eight carbon chain counterpart, PFOS 
(ATSDR, 2018). The similarities of the alkane chain to fatty acids are also thought to be 
associated with toxicity of longer chain compounds such as PFOA, which partitions to a greater 
degree to the liver than shorter chain molecules such as PFBA (ATSDR, 2018). Compared to 
humans, animal models have much faster elimination rates of PFAS with rats and mice 
eliminating most PFAS in a matter of hours to several days (ATSDR, 2018). It is also important 
to note that PFAS half-life estimates in humans may be overestimated due to persistent exposure 
to these environmental contaminants (Olsen et al., 2017). In other words, continual exposure 
from various sources means that the human body burden of PFAS also is persistent.  
Toxicity 
Resulting from the settlement of a class action lawsuit against DuPont in 2001, the C8 
Science Panel began a massive prospective study of residents of the mid-Ohio River Valley, 
where a DuPont facility (Washington Works) in West Virginia had been releasing PFAS, mostly 
PFOA, into the river and air since 1951 (Frisbee et al., 2009). The study was conducted from 
2005-2006 and collected serum samples, residential histories, and questionnaire responses from 
69,000 residents (Frisbee et al., 2009; Shin et al., 2012). This became known as the C8 Health 
Project and data from this study highlight human health outcomes associated with PFOA, and to 
a degree, PFOS exposure (Frisbee et al., 2009; Steenland et al., 2009). Scientists from the C8 
Health Project reported that median PFOA serum levels for over 50,000 residents in southeastern 
Ohio and West Virginia were six times greater than the general population while workers at the 
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Washington Works facility had serum levels of 1,000 ng/mL, on average, in 2004 ((Frisbee et al., 
2009; Sakr et al., 2007; Shin et al., 2012). Chronic exposure to PFOA in this population has been 
associated with increases in pregnancy-induced pre-eclampsia and hypertension, increased 
diagnosis of elevated serum cholesterol, increased risk of thyroid disease, increased risk of 
ulcerative colitis, and increased risk of kidney and testicular cancer (Savitz et al., 2012; 
Steenland et al., 2010; Steenland et al., 2012). The 2018 draft Toxicological Profile for 
Perfluoroalkyls by the Agency for Toxic Substances and Disease Registry (ATSDR) identified 
additional adverse health outcomes associated with PFOA and additional PFAS. These outcomes 
include liver damage, increases in liver enzymes and decreases in serum bilirubin, decreased 
antibody response to vaccines, increased risk of asthma diagnosis, increased risk of decreased 
fertility, and small decreases in birth weight (ATSDR, 2018). The International Agency for 
Research on Cancer (IARC) has also concluded that PFOA is a possible carcinogen with 
evidence of increased testicular and kidney cancer observed in highly exposed humans (IARC, 
2017).  
Liver toxicity is a common endpoint observed in studies of experimental animals 
following PFAS exposure, including increases in liver weight, peroxisome proliferation, changes 
in liver enzymes, and eventually, liver cancer (Abbott et al., 2012; Li et al., 2017). The liver 
toxicity observed in rodent studies has been linked to peroxisome proliferator-activated receptor-
α (PPAR-α) induced peroxisome proliferation, resulting in hepatomegaly, necrosis, and liver 
tumor growth at higher doses (Abbot et al. 2012). Peroxisome proliferator activated receptors 
(PPARs) are a family of nuclear hormone receptors that are important for lipid metabolism and 
inflammation and are naturally activated by fatty acids; as long chain PFAS share a similar 
structure to fatty acids, PFAS can also activate PPARs (Li et al., 2017). Peng et al., in a 2013 
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metabolomics study, showed that PFOA disrupted a variety of metabolic functions in a human 
immortalized liver cell line. This study demonstrated that PFOA had potent changes in lipid 
homeostasis, including an increase in cholesterol biosynthesis, increased biomarkers and 
expression of multiple genes involved in fatty acid transportation and oxidation (Peng et al., 
2013). One such gene change was an induction of ACOX1 transcription, which encodes the first 
gene in the fatty acid beta-oxidation pathway. Interestingly, at the high dose administered in the 
study, (50mg/L), multiple changes were identified in biomarkers and genes involved in 
nucleotide and amino acid metabolism as well (Peng et al., 2013). While PPAR-α appears to be a 
dominant pathway of liver toxicity leading to liver tumors in rodents, as humans only have one-
tenth the amount of liver PPAR-α, some in the scientific community discount the relevance of 
PPAR-α activation by PFAS as a relevant pathway for any toxicity in humans. The Peng et al., 
study however, identified that these alterations occurred without changes in PPAR-a 
expression/signaling in human liver cells (Peng et al., 2013). Furthermore, numerous studies of 
mice lacking a fully functional PPAR-α report that hepatomegaly and peroxisome proliferation 
still exist, although to a reduced degree, indicating that the toxic effects of PFAS on the liver are 
not limited to PPAR-α activation and are thus still important for human toxicity (Abbott et al., 
2012; DeWitt et al., 2016; Filgo et al., 2015; Li et al., 2017; Yang et al., 2002).  
The immune system appears to be sensitive to PFAS exposure, which is supported by the 
US NTP conclusion that PFOA and PFOS are presumed to be immune hazards in humans (NTP, 
2016). This conclusion was based on data from both epidemiological studies of humans and data 
from experimental animal studies. One such epidemiological study was of residents of the Faroe 
Islands, a community where dietary intake of marine food was associated with increased 
exposure to PFAS (Grandjean et al., 2012). This study reported that a doubling of serum PFOA 
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and PFOS concentrations in five-year-old children was associated with a loss of clinical 
protection from tetanus and diphtheria vaccines at age seven (Grandjean et al., 2012). This study 
also observed that maternal PFOS serum levels with a mean of 27.3 ng/mL were negatively 
associated with the child’s diphtheria antibody concentrations (Grandjean et al., 2012). 
In another epidemiological study of families from the Norwegian Mother and Child 
Cohort Study (MoBa), it was observed that four PFAS at the respective median serum 
concentrations, PFOA (1.1ng/mL), PFOS (0.3 ng/mL), PFHxS (0.3 ng/mL), and 
perfluorononanoic acid (PFNA) (5.5ng/mL), were all negatively correlated with the levels of 
anti-rubella antibodies of the 56 children tested at three years of age (Granum et al., 2013). A 
follow-up study by Impinen et al., (2019) using the MoBa cohort, looked at approximately 1000 
mother/child pairs over seven years to assess allergy and asthma outcomes. This study looked at 
six different PFAS including PFOS, PFOA, PFHxS, PFNA, perfluoroundecanoic acid 
(PFUnDA) and perfluoroheptanesulfonate (PFHpS), all of which were detectable in serum of the 
general population, with PFOS being the highest followed by PFOA. Contrary to the previous 
MoBa cohort, this study did not investigate antibody levels but instead focused on three types of 
health outcomes: doctor-diagnosed asthma, eczema, and allergies, parent-reported asthma and 
allergy-related symptoms, and parent-reported number of infections from age 0-3 and 6-7 
(Impinen et al., 2019). While the study showed little evidence of a relationship between prenatal 
exposure and allergy outcomes except for an inverse relationship of PFUnDA and eczema in 
girls, it did support the previously identified immunosuppressive effects of PFAS with an 




Animal studies also support the observation of immune effects in humans; numerous 
rodent studies indicate that PFOA and PFOS are immunotoxic. Peroxisome proliferation from 
PFOA exposure also appears to be partially linked to its immune-system toxicity as mice given 
relatively high doses of PFOA experience splenic and thymic atrophy and changes in 
lymphocyte subpopulations that are significantly reduced in PPAR-α null mice (DeWitt et al., 
2016; Yang et al., 2002; Yang et al., 2001). While numerous studies have shown changes in 
lymphocyte subpopulations as well as splenic and thymic atrophy (DeWitt et al., 2016; Loveless 
et al., 2008),  the “gold standard” for evaluation of the immunotoxicological potential of 
exogenous agents has long been the T-cell dependent antibody response (TDAR), which is used 
to evaluate the antibody response to specific antigens administered to live animals. Our lab 
previously identified a lowest observed adverse effect level (LOAEL) of 3.75 mg/kg for PFOA 
after a 15-day exposure in mice (DeWitt et al., 2008). Other studies have demonstrated that 
PFOS has a broader range of LOAELs, from 0.02-0.8 mg/kg, (Dong et al., 2009; Zheng et al, 
2009, Peden-Adams et al., 2008). Based on their presence in drinking water supplies and 
growing scientific evidence of toxicity, the US EPA set a lifetime drinking water health advisory 
level of 70 ng/L for the combined concentration of PFOA and PFOS (US EPA, 2016a, 2016b). 
This value was deemed to be of minimal risk for susceptible populations, primarily based on 
developmental outcomes, but these levels are also supported by studies using immune endpoints.  
Public Health 
Due to their environmental persistence, ability to bioaccumulate, and a growing body of 
toxicological evidence associated with PFAS exposure, the US EPA in cooperation with the 3M 
Company, fostered a US-based phase-out of several PFOA and PFOS precursors and PFAS-
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related products, starting with PFOS in 2002 and PFOA in 2015 (US EPA, 2015). However, this 
has led to a rise in the production of new PFAS alternatives, touted as having more favorable 
environmental and toxicological properties (Bowman, 2015; Gomis et al., 2018; Hopkins et al., 
2018; Shea, 2018; Wang et al., 2017). This family of alternatives primarily consists of per- and 
poly-fluorinated ether carboxylic acids (PFECA). One such PFECA of importance is the PFOA 
replacement 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate, known by its trade name 
GenX (Gomis et al., 2018; Hopkins et al., 2018). The manufacturer of GenX claims it has a 
favorable environmental and toxicological profile due to is shorter, branching chain, (Figure 1), 
and being less bio-accumulative in the environment (Shea, 2018). Despite these claims, this 
PFECA has become a compound of concern due to its presence in the water systems of several 
major cities including Wilmington NC, Parkersburg WV, and Dordrecht, Netherlands (Gomis, et 
al. 2015; Hopkins et al., 2018).  
Emerging PFAS in North Carolina 
The Chemours Company, a spin-off of DuPont, has a fluoropolymer production facility 
located just south of Fayetteville, NC, on the Cape Fear River, and has been producing GenX 
and various other fluorinated chemicals for years (Sun et al., 2016). According to a consent order 
with NC Department of Environmental Quality (NC DEQ), all wastewater from the facility 
containing GenX were to be shipped off-site for disposal (NC DEQ, 2017). Yet, in 2015, Dr. 
Mark Strynar and colleagues of the US EPA identified GenX downstream of the Chemours site, 
and later Sun et al. (2016) identified concentrations of up to 4,500 ng/L in the Cape Fear River 
(Strynar et al., 2015; Sun et al., 2016). Water from the Cape Fear River serves the drinking water 
needs of several populated areas downstream of the fluoromanufacturer, including Wilmington, 
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NC, and according to Chemours, GenX and other PFECA have been released as wastewater into 
this water source since the 1980s (NC DEQ, 2018). This raises great public concern regarding 
the potential health risks of being exposed to these unknown compounds. Sun et al., (2016) 
identified that multiple PFECA were not filtered out in water treatment plants and thus passed 
into the drinking water of communities downstream of the Chemours facility. Later, Hopkins et 
al., (2018) identified multiple PFECA present in finished drinking water, including perfluoro 2-
methoxyacetic acid (PFMOAA), which is the shortest chain PEFCA as well as the dominant 
PFAS identified in the Cape Fear River, with an approximate concentration of 35,000 ng/L in 
June of 2017.   
To our knowledge, no published studies of the toxicity of PFMOAA exist. Several 
studies exist about the toxicity of GenX, including a study of chronic toxicity that identified no 
observed adverse effect levels (NOAELs) of 0.1 and 1 mg/kg in male and female Sprague-
Dawley rats, respectively, based on liver and kidney effects (Rae et al. 2015). This study 
identified that male mice receiving 50 mg/kg had increased liver enzymes in circulation, evident 
of liver injury, as well as hepatomegaly and increased number of adenomas at 500 mg/kg, 
consistent with other PPAR-α agonists (Rae et al., 2015). A more recent study by Rushing et al. 
(2017), evaluated immune responses in mice as this is a sensitive endpoint for PFAS, as 
previously discussed. They also assessed common biomarkers of PFAS exposure, including liver 
weight and peroxisome proliferation. They identified increases in liver weight at administered 
doses of 10 mg/kg and higher as well as palmitoyl Co-A oxidase activity increases in males at 10 
mg/kg and higher and in females at 100 mg/kg, suggesting PPAR-α activation similar to PFOA 
(Rushing et al. 2017). At the doses administered in this study, they also noted females given 100 
mg/kg had suppressed TDAR. While males did not exhibit immunosuppression, they did have an 
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increase in splenic CD8+, CD4+/CD8+ and CD4-/CD8- T cell subpopulations of 74%, on 
average, at 100 mg/kg (Rushing et al., 2017). Gomis et al., (2015) identified that the PFECA 
alternatives to legacy PFAS had similar chemical properties and environmental fates as their 
predecessors. Another study by Gomis et al., (2018) used hepatotoxicity and internal dose as a 
modeling endpoint and demonstrated that the evidence of a “preferred toxicological profile” for 
these alternatives proposed by chemical manufacturers was negated when the excretion rate was 
taken out of the picture. According to this study, though GenX is excreted faster and less of it is 
partitioned to the liver in animal models due to shortened chain length, when compared using 
internal dose, it is has a greater ability to increase liver weight than, for example, PFOA (Gomis 
et al., 2018). This suggests that high levels of GenX exposure to those consuming contaminated 
water in the Cape Fear River area is a public health concern. Currently, the NC Department of 
Human Health (DHHS) has set a health advisory level of 140 ng/L for GenX, based on 
protection of the most vulnerable populations, bottle-fed infants (NC DHHS, 2017). Still, while 
this health advisory level is aimed to be very conservative, very little is known about the 
environmental fate and toxicity of these emerging contaminants. While these recent studies have 
shed some light on the toxicity of GenX, several other PFECA, PFMOAA, in particular, have yet 
to be studied. Therefore, this research project aims to investigate the immunotoxicological 
effects of PFMOAA in a mouse model and ask whether this newly identified PFAS water 
contaminant has similar effects to its longer chain counterparts.
CHAPTER 2:  30-DAY IMMUNOTOXICITY STUDY OF PFMOAA IN C57BL/6 MICE 
Introduction 
Per- and polyfluoroalkyl substances (PFAS) are a large family of amphiphilic compounds 
composed of alkane tails with fluorine replacing some or all the hydrogens respectively and an 
active head group (Buck et al., 2011). This family of compounds is estimated to contain over 
5,000 different molecules that are widely utilized throughout the world in manufacturing and 
consumer products for their chemical properties that confer water, oil and stain resistance as well 
as temperature and friction resistance (US EPA, 2018, 2019; Wang et al., 2017). These chemical 
properties have made them abundant in water-resistant coatings for textiles and paper products, 
non-stick coatings on cookware and food packaging, and to formulate firefighting foams as well 
as use in aerospace, electronics and automotive industries (ATSDR, 2018; FluoroCouncil, 2014; 
NTP, 2016). Conversely, these same properties of the strong carbon-fluorine bond and 
amphiphilic capabilities have raised environmental health concerns. The strong carbon-fluorine 
bonds do not break down in the environment and allow these compounds to be highly mobile in 
soil and water as well as bioaccumulative (US EPA, 2018; Wang et al., 2017). Due to their 
environmental persistence, ability to bioaccumulate, and a growing body of toxicological 
evidence associated with PFAS exposure, the US EPA in cooperation with the 3M Company 
fostered a phase-out of several precursors and PFAS related products with phase out of U.S. 
production of PFOS in 2002 and U.S. production of PFOA in 2015 (US EPA, 2015). However, 
this has led to a rise in the production of new PFAS alternatives, touted as having more favorable 
environmental and toxicological properties (Bowman, 2015; Gomis et al., 2018; Rushing et al., 
2018; Shea, 2018; Wang et al., 2017). This family of alternatives primarily consists of per- and 
poly-fluorinated ether carboxylic acids (PFECA). One such PFECA of importance is the PFOA 
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replacement 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate, known by its trade name 
GenX (Gomis et al., 2018; Hopkins et al., 2018). This PFECA has become a widely studied 
compound due to its presence in the water systems of several major cities including the 
Wilmington NC, Parkersburg WV, and Dordrecht Netherlands (Gomis et al., 2015; Hopkins et 
al., 2018).  
The Chemours Company, a spin-off of DuPont, has a fluoropolymer production facility 
located just south of Fayetteville, NC, on the Cape Fear River, and has been producing GenX 
and various other fluorinated chemicals for years (Sun et al., 2016). According to a consent order 
with NC Department of Environmental Quality (NC DEQ), all wastewater from the facility 
containing GenX were to be shipped off-site for disposal (NC DEQ, 2017). Yet, in 2015, Dr. 
Mark Strynar and colleagues of the US EPA identified GenX downstream of the Chemours site, 
and later Sun et al. (2016) identified concentrations of up to 4,500 ng/L in the Cape Fear River 
(Strynar et al., 2015; Sun et al., 2016). Water from the Cape Fear River serves the drinking water 
needs of several populated areas downstream of the fluoromanufacturer, including Wilmington, 
NC, and according to Chemours, GenX and other PFECA have been released as wastewater into 
this water source since the 1980s (NC DEQ, 2018). This raises great public concern regarding 
the potential health risks of being exposed to these unknown compounds. Sun et al., (2016) 
identified that multiple PFECA were not filtered out in water treatment plants and thus passed 
into the drinking water of communities downstream of the Chemours facility. Later, Hopkins et 
al., (2018) identified multiple PFECA present in finished drinking water, including perfluoro 2-
methoxyacetic acid (PFMOAA), which is the shortest chain PEFCA as well as the dominant 
PFAS identified in the Cape Fear River, with an approximate concentration of 35,000 ng/L in 




To our knowledge, no published studies of the toxicity of PFMOAA exist. Several 
studies exist about the toxicity of GenX, including a study of chronic toxicity that identified no 
observed adverse effect levels (NOAELs) of 0.1 and 1 mg/kg in male and female Sprague-
Dawley rats, respectively, based on liver and kidney effects (Rae et al. 2015). This study 
identified that male mice receiving 50 mg/kg had increased liver enzymes in circulation, evident 
of liver injury, as well as hepatomegaly and increased number of adenomas at 500 mg/kg, 
consistent with other PPAR-α agonists (Rae et al., 2015). A more recent study by Rushing et al. 
(2017), evaluated immune responses in mice as this is a sensitive endpoint for PFAS, as 
previously discussed. They also assessed common biomarkers of PFAS exposure, including liver 
weight and peroxisome proliferation. They identified increases in liver weight at administered 
doses of 10 mg/kg and higher as well as palmitoyl Co-A oxidase activity increases in males at 10 
mg/kg and higher and in females at 100 mg/kg, suggesting PPAR-α activation similar to PFOA 
(Rushing et al. 2017). At the doses administered in this study, they also noted females given 100 
mg/kg had suppressed TDAR. While males did not exhibit immunosuppression, they did have an 
increase in splenic CD8+, CD4+/CD8+ and CD4-/CD8- T cell subpopulations of 74%, on 
average, at 100 mg/kg (Rushing et al., 2017). Gomis et al., (2015) identified that the PFECA 
alternatives to legacy PFAS had similar chemical properties and environmental fates as their 
predecessors. Another study by Gomis et al., (2018) used hepatotoxicity and internal dose as a 
modeling endpoint and demonstrated that the evidence of a “preferred toxicological profile” for 
these alternatives proposed by chemical manufacturers was negated when the excretion rate was 
taken out of the picture. According to this study, though GenX is excreted faster and less of it is 
partitioned to the liver in animal models due to shortened chain length, when compared using 
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internal dose, it is has a greater ability to increase liver weight than, for example, PFOA (Gomis 
et al., 2018). This suggests that high levels of GenX exposure to those consuming contaminated 
water in the Cape Fear River area is a public health concern. Currently, the NC DHHS has set a 
health advisory level of 140 ng/L for GenX, based on protection of the most vulnerable 
populations, bottle-fed infants (NC DHHS, 2017). Still, while this health advisory level is aimed 
to be very conservative, very little is known about the environmental fate and toxicity of these 
emerging contaminants. While these recent studies have shed some light on the toxicity of GenX, 
several other PFECA, PFMOAA, in particular, have yet to be studied. Therefore, this research 
project aimed to investigate the immunotoxicological effects of PFMOAA in a mouse model and 
ask whether this newly identified PFAS water contaminant has similar effects to its longer chain 
counterparts. 
Materials and Methods 
Animals  
All experimental animal handling and dosing was carried out in accordance with 
procedures approved by the East Carolina University’s Institutional Animal Care and Use 
Committee (IACUC). Male (27) and female (27) C57BL/6 mice, 6-8 weeks old, were purchased 
from Charles River Laboratories and after a weeklong acclimation period, were weight matched 
within cage and then assigned to groups of 3/cage. Animals were divided into 6 animals per dose 
group except for the 7.5 mg/kg PFOA positive control group that consisted of 3 animals/sex. 
Animals were housed with access for food and water ad libitum, and kept at 73°F with a 12:12 h 
light-dark cycle. 
Dosing and Immunizations 
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Dosing solutions of PFMOAA (graciously gifted by Dr. Ralph Mead from the University 
of North Carolina at Wilmington) were prepared fresh weekly in sterile water with 0.5% Tween 
at the following concentrations: 25,000 ng/L, 2,500,000 ng/L 250,000,000 ng/L. Based on our 
previous studies, dosing solutions were administered at 0.1 ml/10g of body weight, resulting in 
the following mg of PFMOAA/kg of mouse body weight: 0 mg/kg, 0.00025 mg/kg, 0.025 
mg/kg, 2.5 mg/kg, as well as 7.5 mg/kg of PFOA as a positive control. Dosing was performed 
via oral gavage, daily, for 30 consecutive days based on individual daily body weights. These 
dosing concentrations were based on published reports of environmental concentrations 
(Hopkins et al., 2018) as well as previous 15-day (DeWitt et al. 2008, 2016) and 28-day exposure 
studies (Rushing et al. 2017). On the 25th day after the initial dose, all mice in all dose groups 
were immunized with sheep red blood cells (SRBCs) via tail vein injections. SRBCs were 
adjusted to 4 × 107 cells in 0.2 ml of sterile saline 
Organ and Body Weights  
Body weights were recorded daily and evaluated for change over the course of the study. 
Immediately following euthanasia, spleen, thymus, brain, liver, heart, and kidneys were removed 
and weights were recorded. All organs except for the spleen and thymus were frozen at -80C for 
later analyses. Fresh spleen and thymus were placed in 6-well plates filled with supplemented 
RPMI 1640 medium (supplemented with 5% fetal bovine serum) and kept on ice to be prepared 
for immunophenotyping.  
Urine Samples 
Urine samples were collected after 24 hours, after five days, and after 15 days of dosing. 
Pooled urine was collected from three animals per cage by placing animals in a clean, empty 
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cage and collecting freely deposited urine. Collected urine was frozen at -80C for future 
analyses of urine PFMOAA concentrations. 
Serum Collection  
Following anesthesia with Isoflurane, blood was collected by neck vein transection into 
collection tubes with a clot activator, allowed to sit for at least 30 minutes, then centrifuged at 
2000 x g for 15 minutes at 4°C. Serum that separated from the clot was then saved and frozen at 
-80C for future analyses. 
Liver Peroxisome Proliferation 
Liver peroxisome proliferation was measured indirectly by palmitoyl CoA oxidase 
activity in liver homogenates, utilizing the H2O2 dependent oxidation of leuco-DCF to DCF. 
Palmitoyl CoA was used as substrate and aminotriazole was added to inhibit interference by 
catalase.  
100 mg of frozen liver per mouse was homogenized in 1 mL of buffer containing 
0.25mM sucrose, 5mM EDTA, and 20mM Tris-HCl. Homogenates were spun at 12,000 x g at 
4°C for 20 minutes and the supernatant was collected. Protein concentration of supernatants was 
determined by the Bradford protein assay and palmitoyl Co-A oxidase activity was measured via 
florescence at one-minute intervals for 10 minutes. Data are expressed as nmoles/min/mg of 
liver.  
Immunophenotyping  
Individual spleen and thymus were aseptically processed into single-cell suspensions by 
gentle grinding and passage through a 70 m nylon filter, following by the addition of 7 mL of 
supplemented RPMI medium. Red blood cells were lysed, and an aliquot of each organ 
suspension was counted on a Nexcelom Bioscience Cellometer Auto 2000 cell counter 
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(Nexcelom Bioscience LLC) to determine cell counts and viability. All samples were adjusted to 
2x107 cells/mL. Optimal concentrations of flow antibodies, reagents, and isotype controls to 
estimate non-specific binding were determined in previous experiments (DeWitt et al., 2016). All 
experimental replicates also included unstained cells as negative controls and single-color 
controls as positive controls to determine color compensation. Monoclonal antibodies 
(ThermoFisher Scientific) coupled to fluorochromes specific for the following markers were 
used: APC anti-mouse CD3e, FITC anti-mouse CD4, and PE anti-mouse CD8a for both spleen 
and thymus samples and FITC anti-mouse CD45RB and PE anti-mouse NK1.1 for spleen 
samples only. Flow cytometric analysis was performed using an BD LSRII flow cytometer (BD 
Biosciences) and 10,000 events were collected from each sample. Dead cells and debris were 
excluded from analysis by using forward scatter and 90° light scatter to establish a gate around 
viable lymphocyte populations. Non-stained cells, isotype controls, and fluorescence minus one 
(FMO) controls were used to distinguish the negative populations from positive populations for 
B cells (spleen only) and T cells (spleen and thymus). Cells were gated based on CD3 expression 
for the subsequent analysis of CD4/CD8 T-subpopulations, but not B cell subpopulations. The 
total number of each cell type was determined from spleen and/or thymus cellularity using 
Microsoft Excel. 
Statistical Analysis 
All weight data and flow cytometry data are presented as mean ± standard deviation. All 
data were analyzed using SAS (SAS Institute), with a one-way analysis of variance (ANOVA) to 
determine dose differences in body and organ weights and immunophenotype. When ANOVA 
indicated a statically significant dose effect, individual Tukey’s post-hoc t-tests were performed. 





Animal Dosing Period Weights 
Weights of animals dosed with PFMOAA did not differ statistically during the dosing 
period (Figure 1). Fluctuations in body weights of male animals on days 1-9 of dosing likely 
reflect the inclusion of personnel newly trained to gavaging and were likely not PFMOAA- or 
PFOA-related. One male animal in the PFOA group died due to a gavage-related injury on the 
fourth day of dosing. One female animal receiving 2.5 mg/kg PFMOAA was euthanized on day 
25 after it was determined, via veterinary consultation, that she had reached a humane endpoint; 
she had urethral/vaginal secretions and upon necropsy, it was determined that one of her kidneys 
was infected. One female animal in the 2.5 mg/kg dose group also had consistently lower body 
weight throughout the dosing period as she had a malocclusion. At the time of euthanasia, four 
male mice had signs of preputial infections, including one from 0.025 mg/kg and three from the 
2.5 mg/kg dose groups. All other animals remained bright, alert, and responsive throughout the 




Figure 1, Average daily body weights for male (A) and female (B) C57BL/6 mice exposed to PFMOAA for 30 days 




Terminal body weights and organ weights corrected by body weight are listed in Table 2. 
No statistical changes were observed in terminal body weights or relative organ weights of 
animals dosed with PFMOAA. Relative liver weights of male and female mice given 7.5 mg/kg 
of PFOA were increased by 135.2% and 211.7%, respectively, relative to the 0 mg/kg group. 
Female mice given PFOA also had a 16.7% decrease in liver-free body weight as well as a 





Table 2. Average body weights and relative organ weights (somatic indices; SI) ± standard deviation for male and 
female C57BL/6 mice exposed to PFMOAA for 30 days. 




2.5 mg/kg 7.5 mg/kg 
PFOA 
Terminal body weight (g) 23.73±1.27 24.42±2.46 24.45±1.50 24.30±1.36 24.45±1.91 
Liver free body weight (g) 22.54±1.20 23.22±2.30 23.16±1.40 23.03±1.23 21.52±0.73 
Liver SI 50.39±1.2 48.76±2.9 52.64±1.9 52.19±4.2 118.52±38.9 
Brain SI 16.97±1.03 16.77±1.14 16.42±0.91 16.47±0.61 17.26±1.17 
Heart SI 4.85±0.43 4.79±0.45 4.96±0.60 5.15±0.53 4.68±0.50 
Kidney SI 12.22±0.40 11.92±0.67 12.36±0.60 12.60±0.67 12.91±0.72 
Spleen SI 3.36±0.33 3.45±1.18 3.82±0.75 3.91±1.24 3.30±0.72 
Thymus SI 2.29±0.39 2.00±0.26 2.19±0.34 2.49±0.44 2.05±0.27 




2.5 mg/kg 7.5 mg/kg 
PFOA 
Terminal body weight (g) 21.20±1.06 21.87±1.07 21.45±0.92 20.66±2.12 19.67±1.36 
Liver free body weight (g) 20.23±0.98 20.81±1.00 20.41±0.85 19.65±1.94 16.86 ±1.00* 
Liver SI 45.66±2.7 48.43±3.0 48.33±1.5 48.72±4.2 142.33±8.4 
Brain SI  19.48±1.29 19.23±0.74 19.09±0.82 20.28±1.69 20.38±1.18 
Heart SI  4.81±0.63 5.50±0.41 5.29±0.45 5.66±0.80 5.44±0.47 
Kidney SI 11.95±0.92 12.36±0.77 11.80±0.72 12.35±0.61 11.97±2.24 
Spleen SI 4.35±0.41 4.79±0.89 4.88±0.27 4.51±0.43 3.30±0.15 * 
Thymus SI 3.48±0.44 3.30±0.54 3.14±0.36 3.41±0.79 2.18±0.79 * 
*Indicates a statistical difference from the 0 mg/kg group (p < 0.05). 
Peroxisome Proliferation 
Peroxisome proliferation as indicated by increased palmitoyl-CoA oxidase activity is 
illustrated in Figure 2. Peroxisomal activity in male animals given PFMOAA did not appear to 
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be increased relative to the 0 mg/kg animals. Female mice given 0.025 mg/kg and 2.5 mg/kg of 
PFMOAA had a 30% and 43% increase in peroxisome enzyme activity, respectively. Male 
animals receiving PFOA had a 98% increase in enzyme activity and females had a 227% 
increase relative to the same-sex 0 mg/kg groups.  
 
Figure 2 Average peroxisomal palmitoyl-CoA oxidase activity in nmoles/min/mg of liver for male and female 
C57BL/6 mice exposed to PFMOAA or PFOA for 30 days. 
Immunophenotyping  
Upon collection and evaluation of thymus samples by flow cytometry, it was determined 
that samples from female mice were inconsistently stained, thus the data were not included here. 
Male animals given 2.5 mg/kg had a statistical increase in splenic CD4+/CD8+ T cells and NK 
cells, relative to the 0 mg/kg group; CD4+/CD8+ T cells were increased by 186% and NK cells 
by 83%. Female animals given PFMOAA had no statistical changes in splenic lymphocytes. 
Female animals given PFOA had 64% fewer NK cells relative to the 0 mg/kg group. Thymus 
samples from male animals given PFMOAA had several changes relative to the 0 mg/kg group. 
T cells in the 0.00025 mg/kg and 0.025 mg/kg dose groups were increased by 59% and 70.5% 
for CD4+ and 57.6% and 60.2% for CD8+, respectively. No statistical changes for splenic or 
thymic CD4-/8- T cells were observed. Although it was not statistically significant, total 
cellularity of spleens from male animals was increased above the vehicle control by 34% and 
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82%, on average, for the 0.025 mg/kg and 2.5 mg/kg doses of PFMOAA. This change in splenic 
cellularity also was associated with the changes observed in specific splenic T cell 
subpopulations for male animals. This pattern was not repeated in the thymuses from male 
animals, but female animals given 7.5 mg/kg of PFOA had a 61% decrease in spleen cellularity 
(p=0.045), which correlates with the changes in splenic T and B cell subpopulations observed for 
female animals. 
Table 3 Average splenic and thymic lymphocyte subpopulations. Values are group averages ± standard deviations 
for the percent of the population of each subpopulation from 10,000 events adjusted by total organ cellularity. 
Male Spleen n= Organ total 
cellularity (e7) 




B cell (e7) NK cell (e6) 
0.0 mg/kg 6 3.29±1.3 3.91±1.5 6.46±3.1 1.3±0.8 6.41±2.3 1.48±0.7 1.01±0.4 
0.00025 mg/kg 5,6 2.83±1.2 3.79±1.4 5.49±2.7 1.59±1.1 6.62±1.9 1.22±0.7 1.11±0.4 
0.025 mg/kg 6 4.42±2.2 4.95±2.5 8.48±5.1 1.02±0.3 8.50±3.9 2.33±1.3 1.22±0.4 
2.5 mg/kg 4,6 6.01±1.9 6.23±1.2 12.6±3.5 3.73±2.3* 12.1±4.2 2.93±0.7 1.85±0.6 * 
7.5 PFOA 2 5.81±0.001 5.79±0.3 10.6±1.4 3.07±1.6 9.5±0.4 2.23±0.1 1.66±0.2 
Female Spleen n= Organ total 
cellularity (e7) 




B cell (e7) NK cell (e6) 
0.0 mg/kg 2 4.51±0.3 5.61±0.5 9.76±0.7 2.69±2.4 8.21±1.1 2.24±0.02 1.37±0.07 
0.00025 mg/kg 6 4.83±1.9 4.94±1.9 8.71±4.2 2.72±1.3 9.13±3.1 2.17±1.0 1.35±0.4 
0.025 mg/kg 6 3.21±0.5 3.82±0.7 4.95±0.9 2.09±1.7 6.64±0.8 1.26±0.2 1.01±0.2 
2.5 mg/kg 5 4.16±1.7 4.92±1.8 8.15±3.5 2.78±0.9 7.73±2.2 1.86±0.9 0.89±0.1 
7.5 PFOA 3 1.75±0.3 ɵ 2.29±0.3 2.95±0.4 1.57±0.3 3.06±0.4 0.7±0.2 0.48±0.1ɵ 
Male Thymus n= Organ total 
cellularity (e7) 




0.0 mg/kg 6 6.35±1.4 0.68± 0.2 2.69±0.4 2.27±0.6 3.25±0.9 
0.00025 mg/kg 6 7.66±1.3 1.08±0.3* 4.24±1.0* 3.03±0.7 4.80±1.4 
0.025 mg/kg 6 7.73±2.1 1.16±0.3* 4.31±0.9* 3.23±1.0 4.42±1.7 
2.5 mg/kg 6 7.47±1.2 0.80±0.2 3.35±1.0 2.81±0.5 4.15±1.0 
7.5 PFOA 2 5.95±0.7 0.64±0.3 2.24±1.2 2.04±0.3 2.06±0.2 
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* indicates statistically significant increase from 0 mg/kg control (p≤0.05) ɵ indicates statistically significant 
decrease from 0 mg/kg control (p≤0.05).   
Discussion 
In this study, we evaluated immune and liver endpoints known to be sensitive to PFAS 
exposure to determine if the emerging contaminant, PFMOAA, could also induce similar 
changes. These endpoints included liver weight, peroxisome proliferation, lymphoid organ 
weights, and lymphocyte subpopulations from the spleen and thymus. Throughout the 30-day 
dosing period, no signs of overt toxicity were observed in mice dosed with PFMOAA and all 
animals gained weight equally across dose groups. Female animals given PFOA began to show 
signs of overt toxicity, as indicated by a decrease in body weight, during the last 10 days of the 
study. In addition, upon euthanasia, these female animals also demonstrated atrophy of lymphoid 
organs and hepatomegaly. Male animals given PFOA also had increases in liver weight and 
palmitoyl-CoA oxidase activity but did not lose body weight. Although previous studies by our 
lab (DeWitt et al. 2008, 2016) demonstrated that 7.5 mg/kg of PFOA was immunotoxic but not 
overtly toxic, these previous studies had a duration of 15 and not 30 days. It is of interest to note 
that one male in the 0.025 mg/kg group and three males in the 2.5 mg/kg group had developed 
preputial infections; it is unclear whether this could be due to immunosuppression. 
Unlike animals given PFOA, mice given PFMOAA did not demonstrate hepatomegaly or 
changes in lymphoid organ weights. Spleens from male animals had a slight increase in all cell 
subpopulations with an increased dose of PFMOAA and CD4+/CD8+ T cells and NK cells were 
statistically increased at 2.5 mg/kg. We interpret this increase in splenic lymphocyte 
subpopulations as associated with increases in spleen total cellularity (Table 3). Thymic 
lymphocytes from male animals had statistical increases in helper and cytotoxic T-cell 
populations at the two lower doses of PFMOAA. While these changes were statistically 
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significant, variability within groups make these data challenging to interpret. The increase in 
spleen cellularity and lymphocyte subpopulations could also have been affected by the preputial 
infections observed in some of the male animals. However, male animals with the infection did 
not have statistical elevations in spleen cellularity compared to animals in the same group that 
did not have a preputial abscesses. Previous studies with PFOA, for example, have shown 
changes in TDAR without changes in lymphocyte subpopulations (Dewitt et al., 2008, 2016; 
Peden-Adams et al., 2008). These changes in lymphocyte subpopulations may therefore not 
necessarily be indicative of changes in immune function. We plan to evaluate the TDAR in 
serum from these animals at a later date.  
 The other endpoints we investigated were based on the ability of PFAS to activate 
peroxisome proliferation and increase liver weight. In previous studies, PFOA and PFOS have 
both been shown to induce peroxisome proliferation and hepatomegaly in rodents (Yang et al. 
2002, DeWitt et al. 2016). PFAS have been shown to act as ligands for PPARs, particularly 
PPAR-α, in part due to the similarity of PFOA and PFOS to long chain fatty acids, endogenous 
ligands for PPARs (Li et al., 2017; Loveless et al., 2008; Peng et al., 2013). Thus we aimed to 
determine if PFMOAA, a very short chain PFAS, also leads to peroxisome proliferation. At the 
doses of PFMOAA administered, increases in liver weight or peroxisome proliferation were not 
observed. We did observe a 43% increase in palmitoyl-CoA oxidase in females given 2.5 mg/kg, 
which may indicate some degree of peroxisome proliferation. Male animals had a slight decrease 
in enzyme activity at the highest dose of PFMOAA. These changes are likely negligible due to 
variability in the assay and the putative short half-life of PFMOAA.  
 One PFAS that shares structural similarity to PFMOAA is PFBA, a four-carbon PFAS 
that lacks the ether group contained by PFMOAA. Biomonitoring studies of 3M employees for 
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PFBA have identified that it has a half-life of roughly two to four days in humans (Change et al., 
2008). While this study was limited by sample size (n=12) and the lack of exposure route data, it 
still identifies the relationship between shorter chain lengths and shorter half-lives (Chang et al., 
2008). The Chang et al., (2008) study also identified that in male CD1 mice, the half-life of 
PFBA is approximately 12-16 hours when they were given a single dose of 10-30 mg/kg of 
PFBA. The excretion rate was much faster in female CD1 mice; they eliminated PFBA in 
approximately 2-3 hours at the three administered doses of 10, 30 and 100 mg/kg (Chang et al. 
2008). A 2009 study by Foreman et al. investigated the ability of PFBA to activate PPARs. In 
this study, wild type (WT) mice transfected with human PPAR-α as well as PPAR-α knockout 
mice were administered PFBA at 35, 175 and 350 mg/kg for 28-days via oral gavage. This study 
identified a dose-dependent increase in relative liver weight for PFBA in both WT and human 
PPAR-α mice but not PPAR-α knock out mice and that PFBA induced PPAR-α transcription in 
both WT and humanized PPAR-α suggesting lipid modulating activity (Foreman et al., 2009). 
While these effects were both lower in the humanized PPAR mice than in WT, it still suggests 
that PFBA can activate PPAR-αrelated metabolic changes in humans. These results also suggest 
that even the shorter chain PFAS can lead to changes in the liver similar to PFOA and other long 
chain PFAS. These data suggest that short-chain compounds such as PFMOAA have 
toxicological potential at certain doses. However, due to the rapid excretion of PFBA in mice, 
this study utilized doses 10-100-fold higher than the doses we used in our study, suggesting 
higher doses are needed to achieve a relevant internal dose of PFMOAA. It is also important to 
note that in a 2018 study of PFAS in the Cape Fear River, approximately 20 ng/L of PFBA was 
measured; PFMOAA was identified as high as 35,000 ng/L (Geosyntec 2018, Hopkins et al 
2018). This is evidence to support public health concerns for PFMOAA as even with a low 
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bioaccumulation potential in humans, high, chronic environmental doses could still lead to 
adverse health outcomes.  
Conclusion 
 At the doses we administered, while being based on environmentally relevant levels 
(Hopkins et al. 2016), likely resulted in extremely low internal doses in our rodent model. Mice 
have been shown to excrete PFAS much more rapidly than humans and with excretion rates 
being inversely correlated with chain length, we suspect that the administered doses of 
PFMOAA led to an internal dose insufficient to induce changes in the endpoints we evaluated 
(Shea 2018, Gomis et al. 2015, 2018). No human data for PFMOAA levels have been published, 
but the high levels of exposure received by Cape Fear River communities are cause for further 
study into the toxicity of PFMOAA and other emerging PFAS.  
 
CHAPTER 3: NK CELL CYTOTOXICITY ASSAY 
Background 
 While the TDAR has long been the gold standard in immunotoxicity testing, it is a 
measure of the humoral adaptive immune response; this leaves out the potential for effects of 
exogenous agents on innate immunity. The natural killer (NK) cell is a mammalian lymphocyte-
related to T and B cells but acts as a part of the innate immune system. NK cells circulate within 
the body and respond to numerous pathological changes. They can identify tumor cells as well as 
virally infected cells without the need for priming, thus being dubbed the “natural” killing cells 
(Abel et al., 2018). Whereas normal healthy cells express major histocompatibility complex 1 
(MHC-1) which the body uses to identify self and non-self, virally infected and cancer cells often 
lose their MHC-1 markers, which NK cells identify (Abel et al., 2018). Once an NK cell detects 
a target, it releases granules containing cytokines such as tumor necrosing factor α (TNFα) and 
interferons (IFN), which signal the target cell to go into apoptosis as well as signaling 
macrophages and other immune cells to the site of infection (Abel et al., 2018). This unique 
natural targeting ability made them a great marker for innate immune function, as the cells can 
be easily harvested from an animal model and incubated with a target that leads to NK cell 
activation. For many years, the method for testing NK cell cytotoxicity utilized the radioactive 
isotope 51 chromium (51Cr), which was taken up by target cells. When co-incubated with NK 
cells (effector cells), the amount of radiation released was used to calculate the number of target 
cells that had been killed by the NK cells (Cholujová et al., 2008). This 51Cr release assay was 
the gold standard for testing the innate immune response but was challenging to run due to the 
short shelf-life of 51Cr and the specialized training and equipment needed for working with 
radiation (Cholujová et al., 2008; Vizler et al., 2002). Due to these challenges, many scientists 
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have moved to using flow cytometric based assays for testing NK cell cytotoxicity. Herein we 
present our novel method for flow cytometric identification of NK cell cytotoxicity.  
Similar to previous 51Cr release assays, we used the mouse lymphoma YAC-1 cell line 
for our target cell as it is readily targeted by NK cells. Several fluorophores could be used, 
including Calcein AM, Carboxyfluorescein succinimidyl ester, or vybrant DiO; we chose to use 
MitoTracker Green (MTG) for labeling due to cost and efficiency. MTG is taken up by the target 
cells and locates to mitochondria, but when the membrane potential is lost in dead cells, it is 
released, making it an optimal live cell stain.  
Methods 
 YAC-1 mouse-derived lymphomas obtained from Sigma-Aldrich (86022801) were 
utilized as our target cell. They were grown in RPMI 1640 culture media containing 10% fetal 
bovine serum (FBS), 1% L-Glutamine, and 1% Pen-Strep antibiotic. These cells grow rapidly 
and cell lines were started approximately five days before use to allow one to two cell passages 
to occur. All experiments were done on the same day of animal euthanasia and organ collection 
to ensure fresh spleen effector cells.  
Target Cell Preparation 
 On the day of organ collection, YAC-1 cells were counted and diluted to a concentration 
of 1x107 cells in two separate tubes. One tube spun and resuspended in 40 mL of RPMI 
containing 10% FBS and 12 µL of MTG and then incubated at 37°C for 20 minutes. The other 
tube was set aside to be used as an unstained control. After incubation, cells were spun, washed 
twice, and resuspended in RPMI containing only 10% FBS and set aside until spleen effector 
cells were ready.  
Effector Cell Preparation 
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Individual spleens were aseptically processed into single-cell suspensions by gentle 
grinding and passage through a 70 m nylon filter, followed by the addition of 7 mL of 
supplemented (+10% FBS) RPMI medium. Red blood cells were lysed, and an aliquot of each 
organ suspension was counted on a Nexcelom Bioscience Cellometer Auto 2000 cell counter 
(Nexcelom Bioscience LLC) to determine cell counts and viability. All samples were adjusted to 
2x107 cells/mL. After splenic effector cells were adjusted to 2x107 cells/mL, they were added to 
three Eppendorf tubes per animal in the following amounts: 150 µL, 50 µL, and 25 µL. These 
tubes were spun at 300 x g and resuspended in 0.5 mL of RPMI+FBS media.  
Co-Incubation and Reading of Results 
Based on a previous study  by Dr. Csava Vizler (2002) and personal contact in 2018, we 
utilized three effector to target cell ratios (E/T) of 5/1, 10/1 and 30/1. We added 0.5 mL of the 
stained YAC-1 cells to each Eppendorf tube and left them to incubate for three hours at 37°C. At 
this time, we also prepared two tubes containing just 1 mL of stained YAC-1 cells to serve as a 
spontaneous release sample and a total cell death control sample. Nothing was added to the 
spontaneous release control whereas 5 µL of 5% Triton X-100 was added to the total cell lysis 
control to lyse all of the cells. After incubation,15 µL of propidium iodide (PI) was added to all 
tubes to stain dead cells. Cells were counted on a BD LSRII flow cytometer (BD Biosciences) 
and 10,000 events were collected from each sample. Unstained control was read first to set the 
proper reading frame for singlet cells and samples were read on PE channels for PI and FITC-A 
channels for MTG. Gates were drawn and calculated around populations of MTG containing 
cells and dead cells without MTG. Data were presented as percent specific lysis using the 
formula PSL = ((% cell death of sample - %spontaneous cell death) / (% maximum cell death - 
%spontaneous cell death)*100).  
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Representative data from a test of this NK cell cytotoxicity assay are presented in Figure 
3; these results are from a 30-day immunotoxicity study of 2,2,3,3-(trifluoromethoxy)propionic 
acid (PFMOPrA) on mice. 
Conclusion 
While studies have shown that the newer flow cytometric methods are less accurate than 
the gold standard of the 51Cr release assay (Cholujová et al., 2008), the method presented here 
has proven to be rapid, cost-effective and simple for the battery of immunotoxicology testing 
performed in our lab as well as a reliable indicator of innate immune system function.
Figure 3. Representative sample of flow cytometry data from an NK cell cytotoxicity assay using MitoTracker 
Green and Propidium Iodide dyes. Includes spontaneous release and total cell lysis controls as well as samples from 
a vehicle control with 5/1 10/1 and 30/1 E/T ratios.  
E/T= 5/1 E/T= 30/1 E/T=10/1 
Spontaneous Release Total Lysis 
CHAPTER 4 CONCLUSIONS AND FUTURE DIRECTIONS 
Emerging PFECA and other PFAS alternatives have become a prevalent subject of 
scientific research and public concern and though manufacturers have touted them as having 
more favorable environmental and toxicological properties their high concentrations in water 
sources around the world require us to question the safety of these contaminants. One such 
affected area is the Cape Fear River downstream of the Fayetteville Works Chemours facility, 
which has been releasing PFAS and related by-products into the river and air for more than a 
decade (NC DEQ, 2017; Sun et al., 2016; Wang et al., 2017). The detection of numerous PFAS 
compounds in the public water systems of over 200,000 residents downstream led to public 
attention and rising concern of those residents. In 2018 the NC General Assembly set aside 
$5,000,000 to fund a NC Policy Collaboratory project named the PFAS Testing Network 
(PFAST Network) (NC Policy Collaboratory, 2019). The PFAST Network is a state-wide 
research collaboration representing expertise from East Carolina University (ECU), University of 
North Carolina at Chapel Hill, Charlotte, and Wilmington, North Carolina State University, 
Duke University, and NC A&T University to examine levels of PFAS in air and drinking water 
and to answer other questions associated withPFAS. As part of this PFAST Network, our lab at 
ECU is working on building toxicological profiles of emerging PFAS contaminants identified in 
the Cape Fear River. We began with the dominant PFAS, PFMOAA. To our knowledge, we are 
the first to investigate the toxicity of PFMOAA and therefore, this study aimed to build a 
toxicological profile of PFMOAA and determine if it leads to similar toxic effects as legacy 
PFAS. 
What We Found 
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In this study, we evaluated immune and liver endpoints known to be sensitive to PFAS 
exposure to determine if the emerging contaminant, PFMOAA, could also induce similar 
changes. These endpoints included liver weight, peroxisome proliferation, lymphoid organ 
weights, and lymphocyte subpopulations. Throughout the 30-day dosing period, no signs of overt 
toxicity were observed in mice dosed with PFMOAA and all animals gained weight equally 
across dose groups. Female animals given PFOA began to show signs of overt toxicity, as 
indicated by a decrease in body weight, during the last ten days of the study. In addition, upon 
euthanasia, these female animals also demonstrated atrophy of lymphoid organs and 
hepatomegaly. Males given PFOA also had increases in liver weight and palmitoyl-CoA oxidase 
activity but did not lose body weight. Although previous studies by our lab (DeWitt et al. 2008, 
2016) demonstrated that 7.5 mg/kg of PFOA was immunotoxic but not overtly toxic, these 
previous studies had a duration of 15 and not 30 days. It is of interest to note that one male in the 
0.025 mg/kg group and three males in the 2.5 mg/kg group had developed preputial infections. 
Whether this could be due to immunosuppression in the mice is unknown. 
Unlike animals given PFOA, mice given PFMOAA did not demonstrate hepatomegaly or 
changes in lymphoid organ weights. Spleens from male animals had a slight increase in all cell 
subpopulations with an increased dose of PFMOAA and CD4+/CD8+ T cells and NK cells were 
statistically increased at 2.5 mg/kg. We interpreted this increase in splenic lymphocyte 
subpopulations as associated with increases in spleen total cellularity (Table 3). Thymic 
lymphocytes from male animals had statistical increases in helper and cytotoxic T-cell 
populations at the two lower doses of PFMOAA. While these changes were statistically 
significant, there was still relatively high variability within groups, which make the data 
challenging to interpret. The increase in spleen cellularity and lymphocyte subpopulations may 
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also have been affected by the preputial infections found in the higher dosed mice but this was 
likely not the only contributing factor. Animals with the infection did not have statistically 
higher spleen cellularity compared to animals in the same group that did not have preputial 
abscesses. Previous studies with PFOA, for example, have shown changes in TDAR without 
changes in lymphocyte subpopulations (DeWitt et al., 2008, 2016; Peden-Adams et al., 2008). 
These changes in lymphocyte subpopulations may therefore not necessarily be indicative of 
changes in immune function.  
 The other endpoints we investigated was based on the ability of PFAS to activate 
peroxisome proliferation and increase liver weight. In previous studies, PFOA and PFOS have 
both been shown to induce peroxisome proliferation and hepatomegaly in rodents (Yang et al. 
2002, DeWitt et al. 2016). PFAS have been shown to act as ligands for PPARs, particularly 
PPAR-α. The other endpoints we investigated were based on the ability of PFAS to activate 
peroxisome proliferation and increase liver weight. In previous studies, PFOA and PFOS have 
both been shown to induce peroxisome proliferation and hepatomegaly in rodents (Yang et al. 
2002, DeWitt et al. 2016). PFAS have been shown to act as ligands for PPARs, particularly 
PPAR-α, in part due to the similarity of PFOA and PFOS to long chain fatty acids, endogenous 
ligands for PPARs (Li et al., 2017; Loveless et al., 2008; Peng et al., 2013). Thus we aimed to 
determine if PFMOAA, a very short chain PFAS, also leads to peroxisome proliferation. At the 
doses of PFMOAA administered, increases in liver weight or peroxisome proliferation were not 
observed. We did observe a 43% increase in palmitoyl-CoA oxidase in females given 2.5 mg/kg, 
which may indicate some degree of peroxisome proliferation. Male animals had a slight decrease 
in enzyme activity at the highest dose of PFMOAA. These changes are likely negligible due to 




Toxicity of Related Compounds 
Although there are no studies on PFMOAA at present, we can evaluate studies of related 
PFAS to predict toxicological effects of PFMOAA. One such compound is the PFOA 
replacement, 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate, known by its trade name 
GenX. GenX, while a much larger PFAS than PFMOAA, has a branched chain and ether group, 
suggesting similarly rapid excretion and has already shown to have significant toxic effects in 
animal models. (Gomis et al., 2018) One such study of chronic toxicity that identified no 
observed adverse effect levels (NOAELs) of 0.1 and 1 mg/kg in male and female Sprague-
Dawley rats, respectively, based on liver and kidney effects (Rae et al. 2015). This study 
identified that male mice receiving 50 mg/kg had increased liver enzymes in circulation, evident 
of liver injury, as well as hepatomegaly and increased number of adenomas at 500 mg/kg, 
consistent with other PPAR-α agonists (Rae et al., 2015). A more recent study by Rushing et al. 
(2017), evaluated immune responses in mice as this is a sensitive endpoint for PFAS, as 
previously discussed. They also assessed common biomarkers of PFAS exposure, including liver 
weight and peroxisome proliferation. They identified increases in liver weight at administered 
doses of 10 mg/kg and higher as well as palmitoyl Co-A oxidase activity increases in males at 10 
mg/kg and higher and in females at 100 mg/kg, suggesting PPAR-α activation similar to PFOA 
(Rushing et al. 2017). At the doses administered in this study, they also noted females given 100 
mg/kg had suppressed TDAR. While males did not exhibit immunosuppression, they did have an 
increase in spleenic CD8+, CD4+/CD8+ and CD4-/CD8- T cell subpopulations of 74%, on 
average, at 100 mg/kg (Rushing et al., 2017). Gomis et al., (2015) identified that the PFECA 
alternatives to legacy PFAS had similar chemical properties and environmental fates as their 
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predecessors. Another study by Gomis et al., (2018) used hepatotoxicity and internal dose as a 
modeling endpoint and demonstrated that the evidence of a “preferred toxicological profile” for 
these alternatives proposed by chemical manufacturers was negated when the excretion rate was 
taken out of the picture. According to this study, though GenX is excreted faster and less of it is 
partitioned to the liver in animal models due to shortened chain length, when compared using 
internal dose, it is has a greater ability to increase liver weight than, for example, PFOA (Gomis 
et al., 2018).  
One PFAS that shares structural similarity to PFMOAA is PFBA, a four-carbon PFAS that lacks 
the ether group contained by PFMOAA. Biomonitoring studies of 3M employees for PFBA have 
identified that it has a half-life of roughly two to four days in humans (Change et al., 2008). 
While this study was limited by sample size (n=12) and the lack of exposure route data, it still 
identifies the relationship between shorter chain lengths and shorter half-lives (Chang et al., 
2008). The Chang et al., (2008) study also identified that in male CD1 mice, the half-life of 
PFBA is approximately 12-16 hours when they were given a single dose of 10-30 mg/kg of 
PFBA. The excretion rate was much faster in female CD1 mice; they eliminated PFBA in 
approximately 2-3 hours at the three administered doses of 10, 30 and 100 mg/kg (Chang et al. 
2008). A 2009 study by Foreman et al. investigated the ability of PFBA to activate PPARs. In 
this study, wild type (WT) mice transfected with human PPAR-α as well as PPAR-α knockout 
mice were administered PFBA at 35, 175 and 350 mg/kg for 28-days via oral gavage. This study 
identified a dose-dependent increase in relative liver weight for PFBA in both WT and human 
PPAR-α mice but not PPAR-α knock out mice and that PFBA induced PPAR-α transcription in 
both WT and humanized PPAR-α suggesting lipid modulating activity (Foreman et al., 2009). 
While these effects were both lower in the humanized PPAR mice than in WT, it still suggests 
40 
 
that PFBA can activate PPAR-αrelated metabolic changes in humans. These results also suggest 
that even the shorter chain PFAS can lead to changes in the liver similar to PFOA and other long 
chain PFAS. These data suggest that short-chain compounds such as PFMOAA have 
toxicological potential at certain doses. However, due to the rapid excretion of PFBA in mice, 
this study utilized doses 10-100-fold higher than the doses we used in our study, suggesting 
higher doses are needed to achieve a relevant internal dose of PFMOAA.  
Currently, the NC Department of Human Health (DHHS) has set a health advisory level 
of 140 ng/L for GenX, based on protection of the most vulnerable populations, bottle-fed infants 
(NC DHHS, 2017). Still, while this health advisory level is aimed to be very conservative, very 
little is known about the environmental fate and toxicity of these emerging contaminants. The 
recent Consent Order and public outcry have led to the Chemours Fayetteville facility to 
implement source control measures of wastewater contaminated with PFAS (NC DEQ, 2017; 
Hopkins et al., 2018). This has resulted in a significant decrease in levels of PFMOAA in the 
Cape Fear River as evidenced by an April 30th, 2019, report from the Cape Fear Public Utility 
Authority (CFPUA), which reported levels of PFMOAA in finished water of 6.11 ppt (CFPUA, 
2019). Though these levels are below most health advisory levels for known PFAS, it is still the 
dominant PFAS present in drinking water and the length and levels of exposure before its 
identification in 2015 are still unknown. PFMOAA was identified as high as 35,000 ng/L 
(Geosyntec 2018, Hopkins et al., 2018), which suggests that historical levels of PFMOAA 
exposure could have been quite high and persistent, even with its low bioaccumulation potential. 
The health outcomes associated with such an exposure have yet to be evaluated.  
Conclusions and Future Directions  
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At the doses we administered, while being based on environmentally relevant levels 
(Hopkins et al. 2016), likely resulted in extremely low internal doses in our rodent model. Mice 
have been shown to excrete PFAS much more rapidly than humans and with excretion rates 
being inversely correlated with chain length, we suspect that the administered doses of 
PFMOAA led to an internal dose insufficient to induce changes in the endpoints we evaluated 
(Shea 2018, Gomis et al. 2015, 2018). No human data for PFMOAA levels have been published, 
but the high levels of exposure received by Cape Fear River communities are cause for further 
study into the toxicity of PFMOAA and other emerging PFAS. To this end, we developed a 
novel NK cell cytotoxicity assay to investigate the effects of PFAS on innate immune system 
function. Unfortunately, we were unable to utilize this assay for the PFMOAA project, but we 
have employed it in subsequent projects. As a part of the PFAST Network, our lab has 
committed to evaluating several of the emerging PFAS contaminants identified in NC for their 
ability to induce adverse health outcomes in the immune system. While there are still many 
PFAS identified in the environment that have little to no toxicological data, a follow-up study of 
PFMOAA at administered doses that will better reflect internal doses experienced by 
chronically-exposed humans is warranted. 
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